Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1677201 | 0.93 | MAPT (0.31) | MAPT | |
| SCHEMBL97446 | 0.89 | ALDH1A1 (0.40) | ALDH1A1LMNAMAPTSMN1; SMN2TDP1 | |
| SCHEMBL129813 | 0.88 | L3MBTL1 (0.32) | ALDH1A1LMNAMAPTSMN1; SMN2TDP1 | |
| SCHEMBL130128 | 0.86 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL130580 | 0.86 | GSK3B (0.39) | ALDH1A1LMNAMAPTSMN1; SMN2TDP1 | |
| SCHEMBL101563 | 0.84 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL1679587 | 0.82 | ALDH1A1 (0.34) | ALDH1A1LMNAMAPTSMN1; SMN2TDP1 | |
| SCHEMBL1286289 | 0.82 | USP2 (0.32) | MAPT | |
| SCHEMBL10192909 | 0.81 | ALDH1A1 (0.34) | ALDH1A1LMNAMAPTSMN1; SMN2TDP1 | |
| SCHEMBL100664 | 0.81 | LMNA (0.45) | ALDH1A1LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088765-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088765-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | PNP, TYMP, DPYD | ALDH1A1 336/4885LMNA 3984/4885MAPT 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.